Candida krusei transmission among hematology patients resolved by adapted antifungal prophylaxis and infection control measures

Journal of Clinical Microbiology

Volumn 44, Issue 3, 2006, Pages 1111-1114

  Vos, Margreet C ^a   Endtz, Hubert P ^a   Horst Kreft, Deborah ^a   Doorduijn, Jeanette ^a   Lugtenburg, Elly ^a   Verbrugh, Henri A ^a   Löwenberg, Bob ^a   De Marie, Siem ^a   Van Pelt, Cindy ^a   Van Belkum, Alex ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; FLUCONAZOLE; FLUCYTOSINE; FUNGAL DNA; KETOCONAZOLE; VORICONAZOLE;

AGAR GEL ELECTROPHORESIS; ARTICLE; BACTEREMIA; BLOOD CULTURE; CANDIDA KRUSEI; CANDIDIASIS; CLINICAL ARTICLE; CONTROLLED STUDY; EPIDEMIC; FUNGAL COLONIZATION; FUNGEMIA; FUNGUS CULTURE; FUNGUS TRANSMISSION; GENOTYPE; HAND WASHING; HEMATOLOGY; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; MORTALITY; NEUTROPENIA; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; FUNGEMIA; GENOTYPE; HEMATOLOGIC DISEASES; HUMANS; LONGITUDINAL STUDIES; NETHERLANDS; NEUTROPENIA;

FUNGI; ISSATCHENKIA ORIENTALIS;

EID: 33644898590     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.44.3.1111-1114.2006     Document Type: Article

References (11)

1. Berger, C., R. Frei, A. Gratwohl, A. Tichelli, B. Hafliger, and B. Speck. 1988. A Candida krusei epidemic in a hematology department. Schweiz. Med. Wochenschr. 118:37-41.
2. Carlotti, A., F. Chaib, A. Couble, N. Bourgeois, V. Blanchard, and J. Villard. 1997. Rapid identification and fingerprinting of Candida krusei by PCR based amplification of the species-specific repetitive polymorphic sequence CKRS-1. J. Clin. Microbiol. 35:1337-1343.
3. Eggimann, P., J. Garbino, and D. Pittet. 2003. Management of Candida species infections in critically ill patients. Lancet Infect. Dis. 3:772-785.
4. Marr, K. A., K. Seidel, T. C. White, and R. Bowden. 2000. Candidemia in allogenic blood and marrow transplant patients: evolution of risk factors after the adoption of prophylactic fluconazole. J. Infect. Dis. 181:309-316.
5. Noskin, G. A., J. Lee, D. M. Hacek, M. Postelnick, B. E. Reisberg, V. Stosor, S. A. Weisman, and L. R. Peterson. 1996. Molecular typing for investigating an outbreak of Candida krusei. Diagn. Microbiol. Infect. Dis. 26:117-123.12.
6. Pfaller, M. A. 1996. Nosocomial candidiasis: emerging species, reservoirs, and modes of transmission. Clin. Infect. Dis. 22:S89-S94.
7. Puzniak, L., S. Teutsch, W. Powderly, and L. Polish. 2004. Has the epidemiology of nosocomial candidemia changed? Infect. Control Hosp. Epidemiol. 25:628-633.
8. Rex, J. H., T. J. Walsh, J. D. Sobel, et al. 2000. Practice guidelines for the treatment of candidiasis. Infectious Diseases Society of America. Clin. Infect. Dis. 30:662-678.
9. Shemer, R., Z. Weissman, N. Hashman, and D. Kornitzer. 2001. A highly polymorphic degenerate microsatellite for molecular strains typing of Candida krusei. Microbiology 147:2021-2028.
10. Wingard, J. R. 1995. Importance of Candida species other than C. albicans as pathogens in oncology patients. Clin. Infect. Dis. 20:115-125.
11. Wingard, J. R., W. G. Merz, M. G. Rinaldi, T. R. Johnson, J. E. Karp, and R. Saral. 1991. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N. Engl. J. Med. 325:1274-1277.